✦ LIBER ✦

681 DENOSUMAB DELAYS DEVELOPMENT OF MULTIPLE BONE METASTASES IN MEN WITH CASTRATE-RESISTANT PROSTATE CANCER

✍ Scribed by Smith, Matthew; Saad, Fred; Shore, Neal; Oudard, Stephane; Miller, Kurt; Tombal, Bertrand; Sieber, Paul; Fizazi, Karim; Van Veldhuizen, Peter; Damião, Ronaldo; Marx, Gavin; Morote, Juan; Feng, Amy; Dansey, Roger; Goessl, Carsten

Book ID: 118485456
Publisher: Lippincott Williams and Wilkins
Year: 2012
Tongue: English
Weight: 50 KB
Volume: 187
Category: Article
ISSN: 0022-5347
DOI: 10.1016/j.juro.2012.02.763

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Denosumab versus zoledronic acid for tre

Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study

✍ Karim Fizazi; Michael Carducci; Matthew Smith; Ronaldo Damião; Janet Brown; Lawr 📂 Article 📅 2011 🏛 The Lancet 🌐 English ⚖ 840 KB

Re: Denosumab Versus Zoledronic Acid for

Re: Denosumab Versus Zoledronic Acid for Treatment of Bone Metastases in Men With Castration-Resistant Prostate Cancer: A Randomised, Double-Blind Study

✍ Walsh, Patrick C. 📂 Article 📅 2011 🏛 Lippincott Williams and Wilkins 🌐 English ⚖ 110 KB

Denosumab versus zoledronic acid in pati

Denosumab versus zoledronic acid in patients with bone metastases from castration-resistant prostate cancer: Results from a phase 3 randomized trial

✍ J. Brown*; M. Carducci; K. Fizazi; M. Smith; R. Damião; L. Karsh; P. Milecki; H. 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 52 KB

PCN9 Modeling Lifetime Effectiveness of

PCN9 Modeling Lifetime Effectiveness of Denosumab Versus Placebo in Men With Castration Resistant Prostate Cancer (CRPC) at High Risk of Developing Bone Metastasis (BM)

✍ M. Lothgren; G. Hechmati; I. Jacobs; Y. Qian; J. Arellano 📂 Article 📅 2012 🏛 John Wiley and Sons 🌐 English ⚖ 59 KB

Denosumab and bone-metastasis-free survi

Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: results of a phase 3, randomised, placebo-controlled trial

✍ Matthew R Smith; Fred Saad; Robert Coleman; Neal Shore; Karim Fizazi; Bertrand T 📂 Article 📅 2012 🏛 The Lancet 🌐 English ⚖ 216 KB

176 NUMBER NEEDED TO TREAT AND RISK BENE

176 NUMBER NEEDED TO TREAT AND RISK BENEFIT ANALYSIS OF DENOSUMAB VERSUS ZOLEDRONIC ACID IN THE TREATMENT OF CASTRATE-RESISTANT PROSTATE CANCER PATIENTS WITH BONE METASTASES

✍ Xie, Jipan; Diener, Melissa; Wu, Eric; Sorg, Rachael; Yu, Andrew; Namjoshi, Madh 📂 Article 📅 2012 🏛 Lippincott Williams and Wilkins 🌐 English ⚖ 47 KB